These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 6418881

  • 1. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
    Schumacher WA, Lucchesi BR.
    J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881
    [Abstract] [Full Text] [Related]

  • 2. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ, Smith CB, Rosenthal G, Lucchesi BR.
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [Abstract] [Full Text] [Related]

  • 3. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
    Dale J, Thaulow E, Myhre E, Parry J.
    Thromb Haemost; 1983 Oct 31; 50(3):703-6. PubMed ID: 6689091
    [Abstract] [Full Text] [Related]

  • 4. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
    Tanaka T, Morishima Y, Watanabe K, Takahashi M, Shibano T.
    Methods Find Exp Clin Pharmacol; 1995 Dec 31; 17(10):693-700. PubMed ID: 9053590
    [Abstract] [Full Text] [Related]

  • 5. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.
    Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT.
    Circulation; 1984 Jun 31; 69(6):1161-70. PubMed ID: 6546902
    [Abstract] [Full Text] [Related]

  • 6. Thromboxane-mediated activation of platelets and enhancement of platelet uptake onto collagen-coated glass or deendothelialized rabbit aorta. Comparative effects of a thromboxane antagonist (EPO45) and a thromboxane synthetase inhibitor (dazoxiben).
    Menys VC, Davies JA.
    Lab Invest; 1984 Feb 31; 50(2):184-9. PubMed ID: 6546403
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine.
    Gross GJ, Moore J.
    Pharmacology; 2004 Jul 31; 71(3):135-42. PubMed ID: 15161995
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML, Harris DN, Heran CL, Phillips MB, Michel IM, Goldenberg HJ.
    Eicosanoids; 1988 Jul 31; 1(2):85-91. PubMed ID: 2856188
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors.
    Korbut R, Dembińska-Kieć A, Swies J, Zmuda A, Gryglewski RJ.
    Thromb Haemost; 1987 Oct 28; 58(3):827-30. PubMed ID: 3324381
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.